Latest Breaking News On - American nephrology nurses association - Page 1 : comparemela.com

Travere Therapeutics Reports First Quarter 2024 Financial Results

FDA grants Priority Review for sNDA to convert FILSPARI® from accelerated approval to full approval for the treatment of IgAN in the U.S.; PDUFA target action date of September 5, 2024 Received 511.

Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association

Upcoming data presentations underscore the potential for FILSPARI to become a foundational treatment for IgAN and Travere’s leadership and commitment to innovation in rare kidney disease SAN DIEGO,.

Medicare Payment Rule Threatens Access to Life-Sustaining Kidney Care

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

Sonya Leigh Fleming, MSN, FNP

'It was a bloodbath': Rare dialysis complication can kill, and more could be done to stop it – Paradise Post